Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post on X:
“Until we have randomized studies, we will not truly understand the contribution of IO in TKI/IO combinations for non-clear cell kidney cancer.
STELLAR304 and SAMETA are v imp P3 trials that have yet to read out – in the meantime, please consider supporting SWOG PAPMET2, led by Benjamin L Maughan.”
More posts featuring Kidney Cancer.